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The prognostic value of oxygenation index early after allogeneic hematopoetic stem cell transplantation: results of a prospective trial C. S. Schiemanck, G. Höffken, G. Ehninger, M. Bornhäuser, T. Illmer (Dresden, D) Background and objectives: Respiratory failure after allogeneic hematopoetic stem cell transplantation is a major cause of death. Acute lung injury can be defined in the course of lung disease by the continuous monitoring of oxigenation indices (Oxi-Index). Therefore, we monitored Oxi-Indices in a patient group who received allogeneic transplantation between November 2001 and October 2002. Methods: Oxi-Index was defined by the ratio of partial pressure of arterial oxygen (mmHg) to the fraction of inspired oxygen. With reference to the definition of the American-European Consensus Conference Committee for acute respiratory distress syndrome patients with Oxi-Indices below 300 were considered to have acute lung injury (ALI). In a prospective trial we monitored Oxi-Indices twice daily to assess respiratory function during the first 30 days after transplantation. 59 patients can now be evaluated for this time period. Results: During the observation period 15 out of 59 patients experienced ALI even before manifestation of clinical signs of respiratory distress. These patients presented as a high risk group for early transplant complications since 40% of them required admission to the ICU compared to 6.8% of the non-ALI patients (p<0.01). With respect to the time course of oxigenation after transplantation there was a decline of median oxigenation in the entire patient group around day 7 possibly reflecting early pulmonary toxicity but there were no differences between patient groups receiving myeloablative or non-myeloablative conditioning regimens. Frequency of orotracheal intubation was significantly increased in the ALI-patient group with 20% vs. 2,3% in the non-ALI-patient group (p<0,05). Conclusions: Monitoring Oxi-Indices proved to be diagnostically relevant to alert for progressive respiratory failure following allogeneic hematopoetic stem cell transplantation. Decline of Oxi-Indices seems to be an early indicator of respiratory distress, which identifies patients at high risk for early transplant related mortality. An interventional study to prove the impact of noninvasive ventilation in these patients is underway.
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Hematopoietic stem cell transplantation in severe combined immunodeficiency patients: possible influence of donor age on recovery of B-cell function C. Schuetz, A. Schulz, W. Friedrich (Ulm, D) Recovery of B -cell function after hematopoietic stem cell transplantation in severe combined immunodeficiency (SCID) patients remains a major problem. Less than 50% of SCID patients transplanted without conditioning develop a functioning B-cell compartment. Many children require long-term intravenous immunoglobulin. We studied 24 SCID patients (11 T-B+, 7 T-B-, 3 Omenn syndromes, 2 ADA-deficiencies, 1 Zap 70-deficiency), all of them transplanted without preceding chemotherapy from an HLA-identical family donor with non-T-cell-depleted bone marrow or peripheral blood stem cells. Normal T-cell function developed in all patients. When immunoglobulin levels normalized without substitution, patients were vaccinated against diphtheria and tetanus and boosted at least twice before antibody responses were measured. Adequate B-cell function was found in 16 from 24 children of which 9 were T-B+ and 5 were T-B-SCID patients (1 ADA-deficiency, 1 Zap 70-deficiency). Interestingly all but one patient transplanted from a sibling donor (n=11, donor age 2 to 10 years) developed protective antibody titers against recall antigens. In contrast half of the patients receiving a graft from a parental donor (n=6, donor age 21 to 59 years) a re still depending on immunoglobulin substitution. Although this is a heterogenous group of patients with respect to the type of SCID, our data suggest that B -cell recovery in SCID patients transplanted without preceding chemotherapy is influenced by donor age. In our experience transplantation from a sibling donor leads to normalization of B-cell function in most cases, whereas transplantation from adult donors leads only inconsistently to full B cell recovery.
Oral Session: Pediatric diseases O337
Pre-emptive immunotherapy on the basis of increasing mixed chimerism -a powerful option to prevent relapse in pediatric patients with ALL after allo-stem cell transplantation P. Bader, H. Kreyenberg, G. Dueckers, W. Hoelle, R. Handgretinger, P. Lang, J. Greil, D. Niethammer, J. Beck, T. Klingebiel (Tuebingen, D; Memphis, USA; Greifswald, Frankfurt, D) We have recently shown that children who developed increasing mixed chimerism (in-MC) post transplant have a significantly enhanced risk for relapse (p<0.0001). Therefore we initiated a large prospective multi-center study to investigate whether the number of relapses can be reduced either by withdrawal of posttransplant immunosuppression and/or by low dose DLI in the critical stage of in-MC. Highly repetitive determination of hematopoietic chimerism was performed and revealed in 101/163 cases either complete chimerism (CC) or low level MC (LL-MC with a maximum of 1% autologous cells); 46/163 pts developed in-MC and 16/163 children showed decreasing MC (de-MC). Relapses occurred significantly (p<0.0001) more often in patients with in-MC (26/46) than in patients with CC/LL-MC (8/101). None of the 16 de-MC patients relapsed. The probability of event free survival (EFS) for all pts was 0.54 (n=163), for the group of pts with CC 0.67 (n=101), for pts with de-MC 0.66 (n=16) and for pts with in-MC 0.24 (n= 46) (p<0.0001). In the group with in-MC 31/46 pts received immunotherapy, 15/46 did not. Further analysis of the in-MC group showed significantly improved probability of event free survival (EFS) of 0.38 for pts with immunotherapy (n=32) vs. 0.0 for pts without additional therapy (n=15) (p=0.0009). In summary, serial and quantitative analysis of hematopoietic chimerism identifies those pts with the highest risk for relapse and provide a reliable algorithm which justifies additional treatment to individual pts. Initiation of prophylactic immunotherapy is a powerful treatment approach to prevent relapses in children transplanted for acute lymphoblastic leukemias.
